尊龙凯时·人生就是搏(中国区)官方网站

Accelerating innovative R&D and ploughing deeply in anti-virus field!

On the evening of August 18, 2022, Kexing Biopharm Co., Ltd. (hereinafter referred to as "the Company" or "Kexing Biopharm") announced that Shenzhen Kexing Pharmaceutical Co., Ltd. (hereinafter referred to as "Shenzhen Kexing"), a wholly-owned subsidiary of Kexing Biopharm, had recently received the Notice of Acceptance, an administrative license document issued by the National Medical Products Administration (hereinafter referred to as "NMPA"), indicating that its clinical trial application for "human interferon α1b inhalation solution" was accepted.

Main Contents of Notice of Acceptance
1. Product Name: Human Interferon α1b Inhalation Solution
2. Application Item: clinical trial for registration of drugs produced in China
3. Acceptance No.: CXSL2200382G, CXSL2200383G
4. Indication: respiratory syncytial virus-associated lower respiratory infections (pneumonia, bronchiolitis) in children
5. Dosage Form: inhalation preparation

The promotion of the R&D of Human Interferon α1b Inhalation solution will help the Company further optimize the portfolio of antiviral drugs, enrich the product pipelines, enhance the overall R&D capability, and build up the long-term profitability.

Interferon α1b inhalation solution

Interferon (IFN) is a family of protein with broad-spectrum antiviral, anti-tumor and immunomodulatory effects, acting as a key component in body's natural immunity. Interferon α1b inhalation solution represents another major breakthrough in the antiviral field achieved by the Company. It is designed specifically for children by using a nebulizer, which can directly deliver the active ingredients to the lesions, resulting in a faster therapeutic effect, so as to free the pediatric patients from pains caused by injections and improve the compliance.